Currently, FDA-approved CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, have significant therapeutic activity against lung cancer cells in the preclinical studies (Schettini et al., 2018; Hino et al., 2020; La Monica et al., 2020). Here, CDK4 is linked to lung carcinoma.